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Abstract
Background The long-term risk from knee intra-articular (KIA) injections in professional athletes such as ex-footballers 
remains unknown. The use of KIA injections is controversial and remains anecdotally prolific as it is perceived as being safe/
beneficial. The aim of this study was to determine the number, type and frequency KIA injections administered to retired 
professional footballers during their playing careers and the associations with post-career knee osteoarthritis (KOA).
Methods This is a cross-sectional study involving a postal questionnaire (n = 1207) and subsequent knee radiographs in a 
random sample of questionnaire responders (n = 470). Footballers self-reported in the questionnaire whether they had received 
KIA injections and the estimated total number over the course of their playing career. Participant characteristics and football 
career-related details were also recorded. KOA was measured as self-reported knee pain (KP), total knee replacement (TKR) 
and radiographic KOA (RKOA).
Results 44.5% of footballers had received at least one KIA injection (mean: 7.5; SD ± 11.2) during their professional career. 
71% of knee injections were cortisone/corticosteroid based. Multivariate logistic regression, adjusting for age, body mass 
index (BMI) and significant knee injury identified that footballers with injections were two times more likely to have KP 
(OR 1.81, 95% CI 1.40–2.34) and TKR (OR 2.21, 95% CI 1.43–3.42) than those without injections. However, there was 
no association with RKOA (OR 1.30, 95% CI 0.85–2.01). Given, the association with KP and TKR, we found a significant 
dose–response relationship as the more injections a player received (by dose–response groups), the greater the risk of KP 
and TKR outcomes after adjustment for knee injury and other confounders (p for trend < 0.01).
Conclusion On average, 8 KIA injections were given to the ex-footballers during their professional career. The most com-
monly administered injections were cortisone based. These injections associated with KP and TKR after they retired. The 
associations are independent of knee injuries and are dose dependent. The study suggests that there may have been excessive 
use of KIA injections to expedite return to play and this contributed to detrimental long-term outcomes such as KP and TKR 
post-retirement from professional football.
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Key Points 
In this cross-sectional study of 1207 ex-professional 
footballers, over 44% reported receiving symptom-reliev-
ing knee intra-articular injections (predominantly corti-
sone based) during their professional careers. Even after 
adjustment for age, BMI and significant knee injury, 
there was a positive association between intra-articular 
injections and knee pain and total joint replacements, 
including a dose–response relationship with increasing 
number of injections.
This is the largest study of knee intra-articular injections 
received by ex-professional footballers and the findings 
suggest potential historic misuse of these injections in 
the English Football League and their detrimental impact 
on long-term knee osteoarthritis outcomes.
1  Background
The use of intra-articular (IA) injection of local anaes-
thetic or corticosteroid to manage injury-related pain and 
enable early return to play has been reported in elite sport 
such as rugby league and Australian Rules Football [1], 
despite a lack of safety and efficacy data [2, 3]. The Inter-
national Federation of Sports Medicine (FIMS) requires 
that a physician does not administer any treatment which 
may ‘in any way mask pain to enable the athlete’s return 
to practising the sport if there is any risk of aggravating 
the injury’ [4]. Despite this recommendation, the risk from 
IA injections remains largely unknown and its use may 
be amplified due to the risk being perceived as less than 
the potential benefits [5, 6]. Gultekin et al. [7] recently 
reviewed the use of pain-relieving injections in sport and 
concluded there was some evidence of long-term safety 
issues. However, there were neither quantitative data nor 
robust evidence to support their conclusion and no specific 
data for knee joint injections in footballers.
In clinical practice, it is widely accepted that no more 
than four IA corticosteroid injections should be admin-
istered into the same joint in a 12-month period due to 
potential detrimental effects of excessive steroid on car-
tilage and other joint tissue [8]. In a randomised control 
trial, McAlindon and colleagues [9] found that regular use 
of IA corticosteroid injections was associated with greater 
cartilage volume loss but no significant difference in KP 
compared to IA placebo injections at 24-month follow-up. 
Anti-anabolic effects on healthy cartilage have also been 
reported particularly at high doses and durations of IA 
corticosteroid use [10]. The World Anti-Doping Agency 
(WADA) explicitly bans the use of any glucocorticoid such 
as cortisone whilst in competition and bans hyaluronic 
acid both in and out of competition [11]. However, in pro-
fessional football, as with other elite sport, regulation of 
the administration of pain-relieving IA injection is limited 
and the type of injection, extent to which they are pre-
scribed, and long-term follow-up have not been studied in 
detail [1, 6, 7]. Furthermore, WADA and their anti-doping 
regulations simply did not exist for elite footballers who 
played professionally during the 1950s–1980s. Data on 
use of knee IA (KIA) injections in professional footballers 
are limited to small studies (n = 27–100) in which 44–54% 
received knee IA (KIA) injections during their career and 
reported long-term impaired knee-health related quality of 
life, including 97% experiencing KP [12, 13].
Our previous study found that ex-professional football-
ers have more than a twofold increased risk of knee osteo-
arthritis (KOA) outcomes, specifically knee pain (KP), 
radiographic KOA (RKOA), and total knee replacement 
(TKR) compared to the general population [14]. The major 
risk factor associated with these KOA outcomes is knee 
injuries [15]. This study aimed to assess the number, type 
and frequency with which KIA injections have historically 
been administered to professional footballers during their 
careers in the UK, and to determine whether KIA injec-
tions are associated with KP, KOA and TKR, and whether 
the associations are independent of knee injuries.
2  Methods
2.1  Study Design
This is a cross-sectional study involving a postal question-
naire survey and subsequent radiographic assessment in 
a sample of responders [14]. The study was approved by 
the Nottingham Research Ethics Committee 1 (Refs 14/
EM/0045 and 14/EM/0015). All procedures involving 
research participants were in accordance with the ethical 
standards of the Nottingham Research Ethics Committee and 
the University of Nottingham and with the 1964 Helsinki 
Declaration and its later amendments. Informed consent was 
obtained from all individual participants in this study.
2.2  Participants
The inclusion criteria for the study were retired male pro-
fessional footballers aged 40 years and older who held a 
professional contract within the top four tiers of the Eng-
lish Football League. Questionnaires were sent to football-
ers via a variety of football organisations and completed 
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questionnaires returned to the Arthritis Research UK Centre 
for Sport, Exercise and Osteoarthritis, University of Notting-
ham. 4775 questionnaires were distributed, and 1207 ques-
tionnaires were completed and returned (25% response rate) 
[14]. Information was obtained on participant characteris-
tics, details of professional football career and other known 
risk factors for KOA, including significant knee injury. 
Those footballers who indicated willingness to have knee 
radiographs, and who had not previously undergone bilateral 
TKR, were invited to attend their nearest Spire Healthcare 
hospital for knee radiographs. Out of the 860 individuals 
who provided consent for bilateral knee radiographs, 470 
attended their local SPIRE HOSPITAL for a radiographic 
assessment (55% response rate) [14].
2.3  Exposures
Receipt of KIA injections was assessed by the question 
‘have you ever had any injections into your knees?’ If play-
ers replied positively, they were then asked to identify which 
knee was injected and the type of injection used with the fol-
lowing options: cortisone (steroid); anaesthetic (lignocaine); 
do not know or other (please specify). We also asked about 
the maximum number of KIA injections received in any sea-
son and the total number of injections into each knee over 
the course of their professional football career.
2.4  Outcomes
KOA was measured via three outcomes; namely:
1. current KP, defined as “any pain for most days in the 
previous month”, was self-reported from the question-
naire, indicated on a body mannequin,
2. TKR was also self-reported in the questionnaire,
3. RKOA was determined in those respondents who were 
willing to undergo knee radiographs, which were under-
taken as standardised bilateral weight-bearing semi-
flexed (tibio-femoral compartments) and 30 degree 
flexed skyline (patello-femoral compartment) views, 
scored by a single assessor (GSF) using the Nottingham 
Line Drawing Atlas (NLDA) and Kellgren–Lawrence 
Scale. These methods, thresholds and associated reli-
ability measures have been reported previously [14].
2.5  Covariates
Age and body mass index (BMI) were self-reported in the 
questionnaire. Constitutional knee alignment (in early 20s) 
was self-reported and assessed using validated line-drawings 
[16]. In using this instrument, participants separately self-
reported early adult life (early 20s—presumed to be consti-
tutional) knee alignment as severe varus, mild varus, straight 
legs, mild valgus or severe valgus. Those with severe or 
mild varus were categorised as having a varus alignment, 
those with severe or mild valgus as having a valgus knee 
alignment and those with straight legs as neutral alignment. 
Footedness was assessed by asking players which foot they 
would use predominantly to kick a ball. Medication use and 
comorbidities such as gout were self-reported in the ques-
tionnaires. Career duration was derived as the time between 
the start of a professional football career (signed with a pro-
fessional football club) and date of retirement from playing 
professional football (end of contract or retirement). Sig-
nificant knee injury was defined as “one which caused pain 
for most days for at least a 3-month period and resulted in 
an absence from all training and matches during this time”. 
We treated significant knee injury as a binary variable in our 
subsequent analysis.
2.6  Analysis
Descriptive analyses included t test for continuous variables 
and Chi-squared test for dichotomous/categorical variables. 
Associations between IA injections and KOA outcomes were 
determined using logistic regression and reported as odds 
ratio (OR) with a 95% confidence interval (CI) and adjusted 
for age, BMI and significant knee injury. A dose–response 
relationship was examined for each outcome in terms of 
groups of injections. We categorised total number of IA 
injections received into groups (0 injection = Group 1, 1–3 
injections = Group 2, 4–6 injections = Group 3, 7 + injec-
tions = Group 4). We present the OR with 95% CI from 
logistic regression models using injection category (Groups 
2–4) as our exposure variable in adjusted and unadjusted 
analyses with the referent group being Group 1, i.e., no KIA 
injections. Finally, we used the Stata command nptrend to 
perform a nonparametric test for trend across the injection 
groups for our three key outcomes: KP, TKR and RKOA 
[17]. We had little to no missing data and therefore, imputa-
tion methods were not used in these analyses. Data manage-
ment and analysis were performed using Stata version 15.1 
(StataCorp, College Station, TX, USA). Significance was 
determined at either the p < 0.05(*) or p < 0.01(**) level in 
the results.
3  Results
Almost half (537, 44.5%) of the 1207 footballers who 
responded to the questionnaire had received IA injections 
into their knees over the course of their career (Table 1). The 
mean number of injections received was 7.5 (SD: 11.2) with 
a range from 1 to 100 for any one knee over a professional 
career. The mean number of injections into the right and left 
knees was 5.5 (SD: 7.2) and 5.6 (SD: 8.7), respectively. Of 
 G. S. Fernandes et al.
the 1207 footballers, 470 received bilateral knee radiographs 
that were used to determine NLDA and Kellgren Lawrence 
scores. RKOA in any knee using the NLDA scoring was 
present in over half (301, 64%) of ex-footballers.
The most commonly reported KIA injections were cor-
tisone (corticosteroid) only (n = 379, 70.6%), local anaes-
thetic injections only (n = 26, 4.8%) and a combination of 
cortisone and local anaesthetic injections (n = 88, 16.37%). 
However, the nature of 51 injections received was reported 
as unknown.
Over half (56.6%) of the footballers who sustained a sig-
nificant knee injury received an IA injection (Fig. 1). How-
ever, 22.6% of footballers who did not report a significant 
knee injury also received a KIA injection. Of the whole 
Table 1  Ex-footballer 
characteristics including known 
risk factors for KOA outcomes
*p < 0.05; **p < 0.01
a Self-reported constitutional malalignment (includes both varus and valgus)
b Pain medication includes paracetamol, NSAIDS and opioids
c Significant knee injury sustained during football career (time-loss of at least 3  months) 2D:4D 
Ratio = index–ring finger ratio
Characteristic Received Injection Total
Yes (n = 537) No (n = 670)
Age (years), mean (SD) 58.6 (11.0) 59.3 (12.2) 59.0 (11.7)
BMI (kg/m2), mean (SD)** 27.5 (3.1) 27.0 (2.9) 27.2 (3.0)
2D:4D Ratio, n (%) 333 (64.9) 400 (62.6) 733 (63.6)
Malalignmenta, n (%) 99 (18.6) 94 (14.5) 193 (16.4)
Right-footed, n (%) 314 (58.7) 399 (59.8) 713 (59.3)
Pain  medicationb, n (%)** 355 (66.1) 392 (58.6) 747 (61.9)
Gout, n (%)** 85 (15.8) 57 (8.5) 142 (11.8)
Significant  injuryc, n (%)** 440 (81.9) 338 (50.5) 778 (64.5)
Career duration (years), mean (SD)* 14.4 (5.2) 13.5 (5.8) 13.9 (5.6)
Matches played, mean (SD) 474 (229) 458 (250) 465 (241)
Training duration (hours per week), mean (SD) 14.6 (5.2) 14.1 (5.1) 14.3 (5.1)
Fig. 1  Number (%) of football-
ers with knee injury and/or IA 
injection in the all ex-footballers 
(n = 1207)*
*440 (36.5%) injury + injection
338 (28.0%) injury only (no injection)
97 (8.0%) injection only (no injury)
332 (27.5%) no injury + no injection
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population, only 27.5% of the footballers neither sustained 
a significant knee injury nor received an IA injection into at 
least one of their knees.
Footballers had a significant increased risk of all KOA 
outcomes if they had received a KIA injection during their 
career (Table 2). These associations remained significant 
after adjustment for age and BMI. However, after also 
adjusting for knee injury, KIA injections were significantly 
associated with KP [OR: 1.81, 95% CI 1.40–2.34] and TKR 
[OR: 2.21, 95% CI 1.43–3.42], but not RKOA [OR: 1.30, 
95% CI 0.85–2.01]. We ran additional analyses to look 
at patterns of joint space narrowing (JSN) in those who 
received IA injections compared to those who did not and 
found no association and no increase in number of compart-
ments with JSN in those injected.
As cortisone injections were the most common, we also 
conducted sub-group analyses where we compared corti-
sone-only injections (n = 379) to those with no injections 
(n = 663). We found similar results, and these are presented 
in “Appendix 1”.
We created four groups according to the number of injec-
tions, i.e., no injection (n = 670), 1–3 injections (n = 192), 
4–6 injections (n = 103) and 7 + injections (n = 122). to look 
further at the relationship between number of IA injections 
and KP and TKR. We found a significant dose–response 
relationship between the number of IA injections and KP 
and TKR outcomes (p for trend < 0.01) (Table 3).
4  Discussion
This is the first study to report the administration of KIA 
injections in professional footballers during their playing 
careers and to investigate their potential associations with 
later KOA outcomes. The main findings are: (1) 45% of ex-
professional footballers reported having at least one KIA 
injection, predominantly corticosteroid, during their profes-
sional career; (2) the mean number of injections received 
over a professional football career was 7.5 (SD: 11.2) and; 
(3) KIA injections were administered predominantly in the 
context of a significant knee injury; however, even after 
adjusting for injury, KIA injections (predominantly corti-
sone injections) were associated with two subsequent KOA 
outcomes (KP and TKR) and showed a dose-dependent rela-
tionship but not with RKOA.
UK footballers received over twice the number of KIA 
injections during their playing careers than that reported 
in a study of 27 Brazilian ex-professional footballers and 
30 non-sport controls, though that study was powered for 
KOA outcomes rather than IA injections, and the type of 
injection and injection frequency per season were unreported 
[12]. It was, however, similar to another study of Brazil-
ian ex-footballers which reported 54% of players as having 
received IA injections. The ex-players in this sample were 
considerably younger (mean age 46.2 years) and played pro-
fessional football in Brazil where KP management strategies 
including use of KIA injections may vary considerably [13]. 
17% of ex-footballers in our cohort reported receiving an IA 
anaesthetic injection for a significant knee injury which is 
Table 2  KIA injection and risk 
of KOA outcomes in those with 
any injection compared with 
those without any injections
# Radiographic KOA assessed using NLDA instrument
† Adjusted for: age + BMI
‡ Adjusted for: age + BMI + Injury
*p < 0.05; **p < 0.01
Outcome Odds Ratio (95% Confidence Interval)
Crude Adjusted  1† Adjusted  2‡
Knee pain 2.76 (2.18–3.50)** 2.55 (2.01–3.25)** 1.81 (1.40–2.34)**
Radiographic  KOA# 1.60 (1.10–2.35)* 1.66 (1.11–2.50)* 1.30 (0.85–2.01)
Total knee replacement 2.56 (1.76–3.73)** 3.23 (2.13–4.88)** 2.21 (1.43–3.42)**
Table 3  Groups of KIA injection and risk of KOA outcomes
# Radiographic KOA assessed using NLDA instrument
† Adjusted for: age + BMI + injury
*p < 0.05; **p < 0.01
Outcome Odds ratio [95% confidence interval 
(CI)]
Crude Adjusted†
Knee pain
 Group 1 (no IA) Reference Reference
 Group 2 (1–3 IA) 1.77 (1.28–2.44) 1.20 (0.85–1.70)
 Group 3 (4–6 IA) 2.30 (1.50–3.55) 1.49 (0.95–2.35)
 Group 4 (7 + IA) 2.83 (1.87–4.29) 1.79 (1.14–2.77)
 Trend p < 0.01 p < 0.01
Total knee replacements
 Group 1 (no IA) Reference Reference
 Group 2 (1–3 IA) 1.03 (0.60–1.75) 1.14 (1.63–2.06)
 Group 3 (4–6 IA) 2.40 (1.40–4.10) 2.01 (1.10–3.69)
 Group 4 (7 + IA) 2.79 (1.72–4.53) 2.08 (1.18–3.69)
 Trend p < 0.01 p < 0.01
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regarded as unsafe and associated with a high risk of major 
complications [5, 7, 18]. However, evidence from these 
previous reports is restricted to small-scale studies, some 
with just anecdotal reporting [5]. There is a general lack 
of robust information regarding the use of KIA injections 
such as anaesthetic and corticosteroids in the setting of knee 
injury and professional sports. Our results suggest a strong 
association, showing a dose–response relationship, between 
receiving KIA injections and later KP and TKR. This trend 
remains even after adjustment for knee injury suggesting 
that injections themselves may have a significant detrimental 
effect on the long-term knee joint health of ex-professional 
footballers.
Although most footballers who received an IA injection 
had sustained an injury, 18% received an IA injection with-
out reporting a significant knee injury. This questions the 
reasoning for such IA injections and raises the possibility 
of players’ recall error or potentially inappropriate health 
professional practice in the context of professional football, 
for example, using IA injection for muscle strains, sprains 
or acute cartilage damage to minimise loss of play and per-
formance during matches and practice sessions. It is worth 
addressing that if inappropriate IA injections were adminis-
tered, the results presented here reflects behaviour more than 
20 years ago which may differ from modern standards and 
practice. Nevertheless, the present data support the principle 
that the type and frequency of KIA injections and the indi-
cations for their use should be monitored and appropriately 
regulated by professional football clubs to ensure they are 
not administered to the detriment of the individual player’s 
long-term joint health.
Although IA corticosteroid injections can be beneficial to 
patients with KP and KOA [19–21], the potential long-term 
risk of cartilage degradation with repeated corticosteroid 
IA injections has long been a concern. This was recently 
highlighted in a 2-year RCT showing more cartilage attri-
tion on certain MRI measures in people receiving regular 
IA injection of corticosteroid compared to placebo [9]. 
However, a direct causal role for IA corticosteroid injec-
tion and subsequent joint damage cannot be confirmed in 
our cross-sectional study design. Although we adjusted for 
known confounders for OA such as age, BMI and significant 
knee injury, there remains the possibility of confounding by 
indication (i.e., players with more severe knee injury and 
problems received more KIA injections). Also, the com-
partmental distribution of cartilage loss shown on X-rays 
was not more widespread in those who received injections, 
which argues against significant corticosteroid-induced 
cartilage changes. Our results show that the risk of KOA 
outcomes was greater for footballers who had received KIA 
injections compared to those who had not. When adjust-
ing for knee injury, the association was significant with KP 
and TKR but not RKOA. This suggests that KIA injections 
are not an independent risk factor for RKOA, but are for 
KP after retirement and TKR. However, as the sample of 
ex-footballers who received bilateral knee radiographs was 
smaller (n = 470) compared to the entire sample (n = 1207), 
these results might be underpowered to detect radiographic 
structural changes. Interestingly, gout was almost twice as 
common in footballers who received a KIA injection. Ex-
professional footballers are prone to significant knee injuries 
in addition to repetitive knee joint microtrauma inflicted by 
training and match play over a prolonged time, both of which 
may predispose to KOA. KOA predisposes to both urate and 
calcium crystal deposition, but equally urate crystal deposi-
tion in bone and cartilage predisposes to joint damage and 
OA. Thus, the higher prevalence of gout may reflect the 
amplification loop involving interplay between urate crystal 
formation and increasing severity of KOA [21, 22] and the 
presence of crystals may cause more symptoms and increase 
the use of intra-articular injections. Those who received KIA 
injections also reported using more pain medication, again 
suggesting more significant injury and long-term damage in 
those receiving injections.
There are several caveats to this work. Firstly, the study 
merely comments on the scale (frequency) of KIA injections 
used over a professional footballer’s career and presents 
associations between KIA injections and KOA outcomes 
with adjustment for a limited number of confounders. We 
cannot account for all confounders, particularly any sig-
nificant knee injury or indeed KIA injections that may have 
been administered post retirement from professional football. 
Secondly, the study is limited by the cross-sectional study 
design which does not allow for any direct causal inferences 
to be drawn between KIA injections and KOA outcomes. 
Although players recalled their history of knee injections 
during their professional careers (predominantly in their 20s 
and 30s) and measured KOA in later life (mean age of cohort 
was 59 years) after they retired, we certainly cannot infer 
causality between KIA and KOA using this study design. 
However, our results are in line with the literature from both 
randomised controlled trials [9] and observational studies 
[23] in the general population. A long-term prospective 
follow-up study from playing professional football through 
to retirement and beyond is required to establish potential 
causal pathways. Thirdly, we are reliant on self-reported 
questionnaire (rather than previously documented) data, 
which is subject to recall bias. Furthermore, we were not 
able to distinguish between pre-, mid- and post-game injec-
tions and midweek injections as we did not include this level 
of granularity within the questionnaire. Lastly, ex-footballers 
with known health problems may have been more likely to 
respond to the questionnaire than ex-footballers with no 
known health issues, thus introducing a selection bias to 
these data.
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5  Conclusion
The study highlights the high number of KIA injections 
(namely cortisone injections) that were historically admin-
istered to ex-professional footballers in the UK and their 
association with KOA outcomes after adjustment for major 
confounders such as injury. However, these results are based 
on ex-footballer’s experience from previous decades and as 
such, may bear little or no relevance to current medical prac-
tices. Current WADA guidelines do not prohibit the intra-
articular use of glucocorticoids; however, in the athletic 
context, this does not in any way suggest that their use is 
to be encouraged. These data provide evidence of potential 
sub-optimal clinical practices of using IA injections, par-
ticularly cortisone injections, to expedite players’ return to 
play and suggest a potential detrimental long-term impact on 
KOA outcomes especially KP after retirement and TKR for 
professional footballers. It is unclear whether these practices 
persist today.
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Appendix 1: KIA injection and risk of KOA 
outcomes in those with cortisone injections 
compared to those without any injections
Outcome Odds ratio (95% Confidence Interval)
Crude Adjusted  1† Adjusted  2‡
Knee pain 2.53 (1.95–
3.29)**
2.42 (1.86–
3.17)**
2.41 (1.84–
3.15)**
Radiographic 
 KOA#
1.68 (1.03–
2.76)*
1.60 (0.97–
2.63)
1.47 (0.88–2.46)
Total knee 
replacement
2.26 (1.51–
3.38)**
2.25 (1.47–
3.36)**
2.30 (1.52–
3.49)**
# Radiographic KOA assessed using NLDA instrument
† Adjusted for: Age + BMI
‡ Adjusted for: Age + BMI + Injury
*p < 0.05; **p < 0.01
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